Home > Name List By c > Conivaptan

CAS No 210101-16-9 , Conivaptan

  • Name: Conivaptan
  • Synonyms: CONIVAPTAN;Conivaptan;
  • CAS Registry Number:
  • Density: 1.298g/cm3
  • Refractive index: 1.698
  • Molecular Weight: 498.583
  • InChI: InChI=1S/C32H26N4O2/c1-21-33-28-19-20-36(29-14-8-7-13-27(29)30(28)34-21)32(38)23-15-17-24(18-16-23)35-31(37)26-12-6-5-11-25(26)22-9-3-2-4-10-22/h2-18H,19-20H2,1H3,(H,33,34)(H,35,37)
  • Molecular Formula: C32H26N4O2
  • Molecular Structure:CAS No:210101-16-9 Conivaptan

Related products

Search by region :

Select to

210101-16-9 CONIVAPTAN

Contact Supplier

210101-16-9 Conivapten

  • United States LGM Pharma [Manufacturer]
  • Tel: 561-981-9994
  • Fax: 561-892-0580
  • Address: 922 Clint Moore Road
    Boca Raton, FL 33487 null,nullUnited States
Contact Supplier

210101-16-9 Conivaptan

  • Conivaptan, Min 99%
  • China Finechemie Co., Ltd. [Manufacturer]
  • Tel: +86-23-99186710
  • Fax: +86-23-99186729
  • Address: 28th Floor Mordern Building,New-Tech Zone400020 ChongqingCHINA Chongqing,nullChina
Contact Supplier

210101-16-9 CONIVAPTAN

  • China Nanjing Chemlin Chemical Industry Co.,Ltd. [Manufacturer]
  • Tel: +86 25 8369-7070/ +86 138 51816776 (Mobile)
  • Fax: +86 25 8345-3275
  • Address: Rm.902 Longyin Plaza,
    No. 217 Zhongshan Rd.
    (N)Nanjing 210009,China null,nullChina
Contact Supplier

Select to

1/1
References of Conivaptan
Title: Conivaptan
CAS Registry Number: 210101-16-9
CAS Name: N-[4-[(4,5-Dihydro-2-methylimidazo[4,5-d][1]benzazepin-6(1H)-yl)carbonyl]phenyl][1,1￠-biphenyl]-2-carboxamide
Synonyms: 4￠-[(2-methyl-1,4,5,6-tetrahydro-imidazo[4,5-d][1]benzazepin-6-yl)carbonyl]-2-phenylbenzanilide
Molecular Formula: C32H26N4O2
Molecular Weight: 498.57
Percent Composition: C 77.09%, H 5.26%, N 11.24%, O 6.42%
Literature References: Nonpeptide, dual vasopressin V1a/V2 receptor antagonist. Prepn: A. Tanaka et al., WO 9503305; eidem, US 5723606 (1995, 1998 both to Yamanouchi); A. Matsuhisa et al., Chem. Pharm. Bull. 48, 21 (2000). Pharmacology: Y. Yatsu et al., Eur. J. Pharmacol. 321, 225 (1997). Binding specificity study: A. Tahara et al., Peptides 19, 691 (1998). Clinical pharmacokinetics: M. Burnier et al., Eur. J. Clin. Pharmacol. 55, 633 (1999). Clinical evaluation in advanced heart failure: J. E. Udelson et al., Circulation 104, 2417 (2001). Review of clinical development: S. A. Doggrell, Curr. Opin. Invest. Drugs 6, 317-326 (2005).
 
Derivative Type: Hydrochloride
CAS Registry Number: 168626-94-6
Manufacturers' Codes: Cl-1025; YM-087; YM-35087
Trademarks: Vaprisol (Astellas)
Molecular Formula: C32H26N4O2.HCl
Molecular Weight: 535.04
Percent Composition: C 71.83%, H 5.09%, N 10.47%, O 5.98%, Cl 6.63%
Properties: Crystals, mp >250°.
Melting point: mp >250°
 
Therap-Cat: In treatment of congestive heart failure.
Keywords: Vasopressin Receptor Antagonist.